In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

In today’s world, losing weight isn’t just about fitting into your old jeans—it’s about reclaiming your energy, confidence, ...

July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

Investing.com -- Bank of America (NYSE: BAC) has unveiled its top 10 U.S. Ideas for the third quarter of 2025, featuring eight Buy-rated stocks and two Underperform calls across ten industries.

Opinions on the new breed of slimming drugs, like Ozempic and Mounjaro, are strong and varied. But what about those who are really in the know?

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

Proteins are the infinitely varied chemicals that make cells work, and science has a pretty good idea how they are made. But ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.